Study analysis · The Journal of Clinical Endocrinology and Metabolism · 2013
In men with heart disease, LDL cholesterol was barely better than a coin flip at predicting who would die — but certain blood fats called ceramides did modestly better.
In men with coronary artery disease, specific ceramide ratios were linked to higher or lower relative risk of cardiovascular death and modestly outperformed LDL cholesterol at distinguishing who died, but absolute risk differences were not reported.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study mostly compares men who died from heart disease with men who didn't, looking at fats in their blood. That can show a link between certain fats and death, but it can't prove the fats are the cause. A small drug test also showed some drugs change those fats, but we don't know if that saves lives.
What’s the bottom line?
Scientists found that certain fats in the blood, called ceramides, are linked to a higher risk of dying from heart disease. They also tested drugs: simvastatin lowered these fats, but ezetimibe did not. People with a gene variant that lowers cholesterol also had lower levels of these fats.
How strong is this study?
The study used careful lab tests and a well-known patient group, which is a strength. But it only looked at men, the drug tests were very small and short, and other things could still confuse the results. So the findings are interesting but not final proof.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
41 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=445)+17.8/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. The primary analysis is a case-control comparison of CAD patients who died versus those who did not, which cannot establish temporality or control for unmeasured confounding. The small randomized drug sub-study can support short-term causal effects on biomarker levels but not on clinical outcomes such as death. The PCSK9 mutation comparison is a genetic association and cannot prove causation.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information was provided in the available text, so potential industry ties or author relationships cannot be assessed.
The provided text lacks a COI/disclosure section, funding statement, and author affiliations. Therefore, COI severity and funder involvement cannot be determined from the available information alone.
Key takeaways
- 01
Ceramide ratios predicted heart disease death better than LDL cholesterol (AUC 0.65-0.68 vs 0.55).
- 02
Simvastatin lowered ceramides by about 25% relative, ezetimibe did not.
- 03
PCSK9 mutation lowered LDL cholesterol by 13% relative and ceramides by 20% relative.
- 04
The study did not report absolute risk, so it's unclear how many fewer deaths would occur.
- 05
The relative reductions in ceramides are promising but need confirmation in larger trials.
Surprising findings
- LDL cholesterol was a poor discriminator of fatal cardiovascular outcome in men with established CAD, with an AUC of 0.55.LDL cholesterol is the cornerstone of heart risk assessment, yet here it was barely better than chance at telling who died from who survived.
- Ezetimibe lowered LDL cholesterol by 21% relative but did not lower risk-associated ceramides; two ceramides were slightly higher by 7.6% and 8.8% relative.If LDL lowering is the main goal, ezetimibe should help. But this study suggests it may not favorably change these specific ceramides.
- PCSK9 R46L carriers had only 13% lower LDL cholesterol relative but 20% lower risk-associated ceramides relative.A small LDL drop was accompanied by a larger ceramide drop, hinting that PCSK9 affects ceramides in a way that is not simply proportional to LDL lowering.
- The lipidomic signature of fatal outcome differed by diabetes status: elevated sphingolipids in nondiabetic men, reduced cholesteryl esters in diabetic men.It challenges the idea that one lipid risk profile applies to all CAD patients.
Practical takeaways
Do not stop or change any cholesterol medication based on this study. If you are curious about advanced lipid testing, ask your doctor whether ceramide testing is appropriate for you.
Ceramide testing is not standard, absolute risk reductions were not reported, and the drug trial was only 14 days in healthy men.
low confidenceWhen you see headlines about heart risk, ask whether the number is relative or absolute. This study reports relative changes like 20% lower ceramides but no absolute risk difference.
Relative changes can sound large even when absolute differences are small or unknown.
high confidenceIf you have heart disease and diabetes, recognize that your risk profile may differ from someone without diabetes. Discuss comprehensive risk assessment with your clinician.
This study was observational and cannot prove that treating one lipid pattern improves outcomes.
medium confidenceWhy this study matters
LDL cholesterol flunks the prediction test
Traditional risk markers could not reliably distinguish men with CAD who died from cardiovascular causes within 3 years from those who remained stable. Cases had only 6% higher total cholesterol relative and 7.5% lower HDL cholesterol relative, and both groups had a median Framingham 10-year risk of 20%. LDL cholesterol had an AUC of just 0.55, barely better than chance.
Many people assume LDL cholesterol is the ultimate heart risk number. This study suggests that in men who already have heart disease, LDL may miss a lot of the real risk.
Ceramide ratios modestly beat LDL
Ceramide ratios Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/20:0)/Cer(d18:1/24:0), and Cer(d18:1/24:0)/Cer(d18:1/24:1) had AUCs of 0.67, 0.65, and 0.68, compared with 0.55 for LDL cholesterol. These associations remained significant after adjustment for traditional risk factors including LDL cholesterol. An AUC of 0.5 is no better than chance; 1.0 is perfect.
This introduces a potential new biomarker that could one day help identify high-risk heart patients better than standard cholesterol tests.
Statins lower ceramides, ezetimibe doesn't
In healthy men, simvastatin 40 mg daily for 14 days lowered LDL cholesterol by 40% relative and lowered multiple ceramide and cerebroside species by about 25% relative to baseline. Ezetimibe 10 mg daily lowered LDL cholesterol by 21% relative but did not lower risk-associated ceramides; two ceramides were slightly higher by 7.6% and 8.8% relative, and one was unchanged.
Two drugs both lower LDL cholesterol, but only one lowered these potentially risky blood fats. That suggests how you lower cholesterol may matter, not just how much.
PCSK9 mutation lowers ceramides more than expected
People carrying the PCSK9 R46L loss-of-function mutation had about 13% lower LDL cholesterol relative and about 20% lower risk-associated ceramides relative compared with non-carriers. The ceramide reduction was comparable to simvastatin despite only a modest LDL cholesterol drop.
It suggests PCSK9 deficiency may affect ceramides through a mechanism beyond simply lowering LDL cholesterol.
Diabetes changes the risky lipid signature
Among men with CAD, the lipidomic signature linked to fatal cardiovascular outcome differed by diabetes status. In nondiabetic men, fatal outcome was associated with elevated sphingolipid species. In diabetic men, fatal outcome was mainly associated with reduced cholesteryl ester species.
It suggests that heart risk may look different in people with and without diabetes, so a one-size-fits-all lipid test may not work.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that certain fats in the blood, called ceramides, are linked to a higher risk of dying from heart disease. They also tested drugs: simvastatin lowered these fats, but ezetimibe did not. People with a gene variant that lowers cholesterol also had lower levels of these fats.
Research results
Ceramide ratios predicted heart disease death better than LDL cholesterol (AUC 0.65-0.68 vs 0.55). Simvastatin lowered ceramides by about 25% relative, ezetimibe did not. PCSK9 mutation lowered LDL cholesterol by 13% relative and ceramides by 20% relative.
What this means - more context
The study did not report absolute risk, so it's unclear how many fewer deaths would occur. The relative reductions in ceramides are promising but need confirmation in larger trials.
To identify molecular lipids associated with fatal outcome in coronary artery disease (CAD) patients and to evaluate the effect of different lipid-lowering drugs on these novel risk lipids.
In a case-control study of male CAD patients, distinct ceramide species and their ratios were significantly associated with cardiovascular death, with areas under the curve (AUC) of 0.65–0.68 compared to 0.55 for LDL cholesterol. Simvastatin 40 mg lowered plasma ceramides by approximately 25% relative to baseline, while ezetimibe 10 mg did not. PCSK9 R46L carriers had 13% lower LDL cholesterol and 20% lower risk-associated ceramides relative to non-carriers. Absolute risk differences were not reported.
Methods Used
Serum lipidomic analysis of 445 male CAD patients from the LURIC cohort (258 cardiovascular deaths within 3 years, 187 controls) using mass spectrometry. Additionally, a randomized trial of simvastatin (n=24), ezetimibe (n=24), or combination (n=24) in healthy males for 14 days, and genetic comparison of PCSK9 R46L carriers (n=19) vs non-carriers (n=868).
Main Finding
Distinct ceramides are associated with fatal CAD outcome independently of traditional risk factors. Simvastatin and PCSK9 deficiency, but not ezetimibe, effectively lower these risk-associated ceramides. The absolute risk reduction for cardiovascular death was not reported.
Confidence Level
Moderate. The case-control design is prone to selection bias, and the drug effects were tested in short-term studies of healthy males. The genetic association is observational and cannot prove causality.
Study Flags
Red Flags
- •Only male subjects from a single cohort
- •Short-term drug trial (14 days) in healthy males
- •Absolute risk differences not reported
Surprising Findings
LDL cholesterol was a poor discriminator of fatal cardiovascular outcome in men with established CAD, with an AUC of 0.55.
LDL cholesterol is the cornerstone of heart risk assessment, yet here it was barely better than chance at telling who died from who survived.
Practical Takeaways
Do not stop or change any cholesterol medication based on this study. If you are curious about advanced lipid testing, ask your doctor whether ceramide testing is appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Moderate probability
on the GRADE evidence scale
This study mostly compares men who died from heart disease with men who didn't, looking at fats in their blood. That can show a link between certain fats and death, but it can't prove the fats are the cause. A small drug test also showed some drugs change those fats, but we don't know if that saves lives.
Strengths
- Large well-characterized LURIC cohort with prospective follow-up
- Blinded adjudication of cardiovascular deaths
- Comprehensive mass spectrometry lipidomics with quality control
Weaknesses
- Case-control design susceptible to confounding and selection bias
- Only male participants included
- Small sample sizes for drug and genetic sub-studies
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that certain fats in the blood, called ceramides, are linked to a higher risk of dying from heart disease. They also tested drugs: simvastatin lowered these fats, but ezetimibe did not. People with a gene variant that lowers cholesterol also had lower levels of these fats.
Research results
Ceramide ratios predicted heart disease death better than LDL cholesterol (AUC 0.65-0.68 vs 0.55). Simvastatin lowered ceramides by about 25% relative, ezetimibe did not. PCSK9 mutation lowered LDL cholesterol by 13% relative and ceramides by 20% relative.
What this means - more context
The study did not report absolute risk, so it's unclear how many fewer deaths would occur. The relative reductions in ceramides are promising but need confirmation in larger trials.
To identify molecular lipids associated with fatal outcome in coronary artery disease (CAD) patients and to evaluate the effect of different lipid-lowering drugs on these novel risk lipids.
In a case-control study of male CAD patients, distinct ceramide species and their ratios were significantly associated with cardiovascular death, with areas under the curve (AUC) of 0.65–0.68 compared to 0.55 for LDL cholesterol. Simvastatin 40 mg lowered plasma ceramides by approximately 25% relative to baseline, while ezetimibe 10 mg did not. PCSK9 R46L carriers had 13% lower LDL cholesterol and 20% lower risk-associated ceramides relative to non-carriers. Absolute risk differences were not reported.
Methods Used
Serum lipidomic analysis of 445 male CAD patients from the LURIC cohort (258 cardiovascular deaths within 3 years, 187 controls) using mass spectrometry. Additionally, a randomized trial of simvastatin (n=24), ezetimibe (n=24), or combination (n=24) in healthy males for 14 days, and genetic comparison of PCSK9 R46L carriers (n=19) vs non-carriers (n=868).
Main Finding
Distinct ceramides are associated with fatal CAD outcome independently of traditional risk factors. Simvastatin and PCSK9 deficiency, but not ezetimibe, effectively lower these risk-associated ceramides. The absolute risk reduction for cardiovascular death was not reported.
Confidence Level
Moderate. The case-control design is prone to selection bias, and the drug effects were tested in short-term studies of healthy males. The genetic association is observational and cannot prove causality.
Study Flags
Red Flags
- •Only male subjects from a single cohort
- •Short-term drug trial (14 days) in healthy males
- •Absolute risk differences not reported
Surprising Findings
LDL cholesterol was a poor discriminator of fatal cardiovascular outcome in men with established CAD, with an AUC of 0.55.
LDL cholesterol is the cornerstone of heart risk assessment, yet here it was barely better than chance at telling who died from who survived.
Practical Takeaways
Do not stop or change any cholesterol medication based on this study. If you are curious about advanced lipid testing, ask your doctor whether ceramide testing is appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Moderate probability
on the GRADE evidence scale
This study mostly compares men who died from heart disease with men who didn't, looking at fats in their blood. That can show a link between certain fats and death, but it can't prove the fats are the cause. A small drug test also showed some drugs change those fats, but we don't know if that saves lives.
Strengths
- Large well-characterized LURIC cohort with prospective follow-up
- Blinded adjudication of cardiovascular deaths
- Comprehensive mass spectrometry lipidomics with quality control
Weaknesses
- Case-control design susceptible to confounding and selection bias
- Only male participants included
- Small sample sizes for drug and genetic sub-studies
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study used careful lab tests and a well-known patient group, which is a strength. But it only looked at men, the drug tests were very small and short, and other things could still confuse the results. So the findings are interesting but not final proof.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
41 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=445)+17.8/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. The primary analysis is a case-control comparison of CAD patients who died versus those who did not, which cannot establish temporality or control for unmeasured confounding. The small randomized drug sub-study can support short-term causal effects on biomarker levels but not on clinical outcomes such as death. The PCSK9 mutation comparison is a genetic association and cannot prove causation.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information was provided in the available text, so potential industry ties or author relationships cannot be assessed.
The provided text lacks a COI/disclosure section, funding statement, and author affiliations. Therefore, COI severity and funder involvement cannot be determined from the available information alone.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
11 researchersIf this is your work, this is how we attribute it on Fit Body Science. Kirill V. Tarasov is listed as the lead author.